This analysis examines the historical and forecast performance for AstraZeneca in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.
Reasons to Purchase
Benchmark AstraZeneca’s performance against key rivals in the ethical pharmaceutical sector
Assess the commercial impact of AstraZeneca’s recent movement into the biologics market, spearheaded by its acquisition of MedImmune
Analyse the exposure of AstraZeneca’s blockbuster portfolio to patent expiration and generic competition through to 2013
